open
serve
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Ask Genius
Apps
IJR News — today's news from every side
Ask Genius
Apps
Trending
China's Novo Nordisk Oral Wegovy Filing Accepted
Business
— 4d
Novo Nordisk trades near its average price target as China regulators accept the oral Wegovy application, underscoring a regulatory catalyst amid strong GLP-1 growth potential. The China market is heating up with Eli Lilly and others racing to offer pill-based options, and analysts project GLP-1 sales in China to surge to around 30 billion yuan in the next five to seven years, driving competition and market leadership shifts.
+5
Share
Novo Nordisk Tests Lower Wegovy Doses
x/novo-nordisk
— Aug 19, 2026
Novo Nordisk is conducting a late-stage study to identify the lowest effective dose of Wegovy, testing two low doses against placebo in 450 participants as it seeks to preserve its share in a obesity drug market projected to exceed $100 billion annually by 2030. The trial, which began on August 12 and runs through 2028, follows competitive pressure from Eli Lilly and comes after Wegovy's recent sales performance, with dose strengths undisclosed.
+4
Share
China obesity rate expected above 65% by 2030
x/people-s-republic-of-china
— Aug 24, 2026
China’s National Health Commission suggests obesity could exceed 65% of the population by 2030, triggering a push by major drugmakers to promote GLP-1 weight-loss injections through indirect public advertising in places like metro stations and stadiums due to bans on direct prescription-drug ads. Companies including Novo Nordisk, Lilly, Pfizer, and Innovent Biologics are vying for market share, with Lilly leading online sales on Alibaba/JD.com and campaigns emphasizing obesity risks and related conditions such as sleep apnea without naming products.
+2
Share
Nestlé Uses AI to Target GLP-1 Users
Health
— Aug 14, 2026
The rapid rise of GLP-1 weight‑loss drugs is reshaping the market as Nestlé leverages AI to turn potential threats into opportunities by developing nutrition products and addressing drug side effects, while major pharma players like Lilly and Novo Nordisk navigate revenue trajectories and competitive disputes. Across the industry, executives see GLP-1 therapies expanding beyond weight loss into broader health benefits, with AstraZeneca highlighting broader applications and regulators flagging safety and counterfeit risks as demand climbs.
+5
Share
IJR
As California Burns Billions To Fail At High-Speed Rail, China Laid Enough Track To Circle America Three Times
Paris Apodaca · 6 min · 6h
Trump Announces $250 Weight Loss Drugs In Latest ‘TrumpRx’ Deal
x/donald-john-trump
— Nov 6, 2025
President Donald Trump unveiled steep discounts on GLP-1 weight loss drugs in deals with pharmaceutical giants Eli Lilly and Novo Nordisk in a Thursday Oval Office announcement. The obesity drugs Zepbound, marketed by…
Share
Ranking
Most underrated cities in America
America's biggest cities hog all the spotlight, while dozens of smaller gems get overlooked despite great food, culture, and character. These underrated cities deserve recognition beyond the usual coastal favorites. Cast your vote and help crown the most underappreciated city in the country.
693 votes · 21 candidates
Pharma Exec Passes Out In Oval Office As Dr. Oz Rushes To His Aid
x/novo-nordisk
— Nov 6, 2025
Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz rushed to the aid of Novo Nordisk executive Gordon Findlay as he passed out inside the Oval Office on Thursday. President Donald Trump, Oz, Health…
Share
